Clinical Trial Update: Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion [Phase 2]

View source ↗

Summary

A Phase 2 safety and proof-of-concept study of ANXV (Annexin A5) in retinal vein occlusion has been completed, reporting collected safety and exploratory data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Vein Occlusion

Drugs mentioned

• ANXV (Annexin A5)

Snippet

Sponsor: Annexin Pharmaceuticals AB | Conditions: Retinal Vein Occlusion | Phase 2 | Status: COMPLETED